There are 3 reasons why our price target had to be increased by 40% and could be raised even higher in the coming months.
Download Report in PDF Or Scroll down to read the complete report below.
Nuvilex Anti-Cancer Valuation
We should note that there are several very important reasons why we have elected to raise our price target on Nuvilex to $0.75 from $0.50.
In our most recent report dated April 18, 2013, we provided a valuation for the Company’s pancreatic cancer treatment alone. Based on recent due diligence, we believe that a valuation for the Company’s anti-cancer efforts must include its breast cancer studies and other factors.
Breast Cancer Study Has Tremendous Value
One, a Phase I/II clinical trial undertaken by Nuvilex affiliate SG Austria was for mammary tumors in dogs. We originally viewed this prospective indication as a potential bonus for investors. However, our research unearthed a large canine tumor trial funded by the U.S. Department of Defense that indicated canine mammary trials are an ideal model for human breast cancer trials. This revelation means that the Company’s trial carries significant weight, given its positive results.
Two, our follow-up research enabled us to discover that FDA-approved treatments for breast cancer are being studied now to treat pancreatic cancer. However, to date, some of these treatments have demonstrated lower efficacy and survival rates in pancreatic cancer patients than with breast cancer patients. Treatments that employ Nuvilex’s cell encapsulation technology have demonstrated greater efficacy in mid-stage clinical trials in advanced pancreatic cancer, than the current “gold standard” single-agent drug for this disease when compared to historical data for that cancer drug, and have also shown promise in preclinical breast cancer studies. It is possible that the results with breast cancer could ultimately show that the cell encapsulation technology can also be substantially positive, and perhaps even more so, for this indication than they are for pancreatic cancer.
Thus, the combination of the true value of the Company’s mammary trial and what could result in greater efficacy to treat breast cancer than pancreatic cancer illustrate huge, previously unrealized value for the stock and potential for Nuvilex.
NVLX is Truly Gearing Up for Future Trials
The Company has taken steps vital to its goal of engaging in late-stage pancreatic cancer clinical trials. The Firm has established a research cell bank in concert with a leading contract research organization in Europe. This cell bank will be used for the production of the Company’s live cell encapsulation offering, which has demonstrated significant ability to activate the cancer pro-drug ifosfamide in close proximity to the pancreatic cancer itself, thus resulting in a high degree of antitumor efficacy with a low toxicity profile for the anticancer drug, in Phase II clinical trials. The Company plans that the late-phase clinical trial in patients with advanced, inoperable, pancreatic cancer will be “first in line” to use the cells produced from the cell bank.
With the launch of the cell bank, the Company has embarked on the first step necessary to ensure the availability of the large number of encapsulated cells that will be required for the commencement of a Phase III pancreatic cancer clinical trial, along with other possible trials that may be done in the future that use the cell encapsulation as part of treatment regimens to treat various forms of cancer. The bank will essentially “grow” the live cells required for encapsulation in which the cells are enclosed in small (about the size of the head of a pin) cellulose-based “beads” or capsules that are then implanted in the pancreatic patient’s body near the cancer itself.
As the Company moves closer to commencing additional trials, substantial increases in valuation will occur.
A slew of recent activity has occurred in the nanomedicine, or nanobiotechnology industry which bodes well for Nuvilex Inc. (OTCQB – NVLX). According to a recent Reuters article, nanomedicine is defined as: “The ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with, hopefully, fewer side effects.”
It sounds very much like the definition for Nuvilex’s Cell-in-a-Box technology.
In the past two months alone, privately held nanobiotechnology leader Bind Therapeutics has closed 3 development deals with drug giants Pfizer, Amgen, and AstraZeneca. Significant upfront dollars have been paid and if all of the proposed drugs under development were to receive approval, it could be worth at least several hundred million dollars to Bind Therapeutics.
It is apparent that the methodology behind the delivery methods of both firms are remarkably similar, as is the primary targeted disease: cancer. In both cases, pro-drugs are encapsulated and targeted directly at the tumor with greater efficacy than traditional methods and with far less toxicity.
Clearly, a great deal of attention and value is beginning to occur for firms developing tiny, targeted delivery systems to treat major diseases like cancer. As Nuvilex edges closer to developing protocols for future trials, the valuation for the Company’s platform is likely to move significantly higher as industry observers may begin to mention the Company in the same breath as the leading nanobiotechnology firms.
Clearly, on a combined basis, NVLX is a bargain at current levels. As NVLX executes on milestone achievements in its key arenas, the stock could rise dramatically higher, aided in part by a likely short squeeze. We rate shares Speculative Buy and introduce our upgraded $0.75 price target.
Recent Trading History For NVLX
Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
This Opportunity Research report was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Goldman Small Cap Research has been compensated by Treasure Coast Health Associates LLC in the amount of $4,000 for a research subscription service. The Firm does not accept any equity compensation. All information contained in this report was provided by the Company. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com